CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
HCV | WEBCAST Back
Webcasts
 
  Release Date 12/6/2012
Expiration Date 12/6/2013
This program has expired. CME credit is no longer available.
     
  Nezam Afdhal, MD
Beth Israel Deaconess
Medical Center
Boston, MA
 
   
     
  Kim Brown, MD
Henry Ford Hospital
Detroit, MI
 
   
     
  Jordan Feld, MD
Toronto Western Hospital
Liver Center
Toronto, Canada
 
   
     
  Michael Fried, MD
University of North Carolina
Chapel Hill, NC
 
   
     
  Ira Jacobson, MD
Weill Cornell Medical College
New York, NY
 
   
     
     
   
     
  Presented for attendees of the 63rd AASLD Annual Meeting (or The Liver Meeting®). This event/function is sponsored by Chronic Liver Disease Foundation and Supported by Vertex Pharmaceuticals. This is not an official function/event of the American Association for the Study of Liver Diseases.  
     
 
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center
Boston, MA
Nezam H. Afdhal, MD, is Chief of Hepatology and director of the Liver Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He is also Professor of Medicine at Harvard Medical School. Dr. Afdhal received his medical degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College Dublin and at Boston University School of Medicine.

Dr. Afdhal’s clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension. He is the director of a clinical trials group focusing on novel treatments of hepatitis B and C, liver fibrosis, and NASH. Additional research interests include basic and translational research in gallstone disease, liver cancer, and liver fibrosis. His research is funded by multiple NIH, industry, and foundation grants.

Dr. Afdhal has served on multiple state and national advisory boards for liver disease. He has also served on the Editorial Boards of and as a reviewer for multiple journals. Dr. Afdhal has published more than 180 papers in journals such as New England Journal of Medicine, Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and 2 books. He is the editor for Journal of Viral Hepatitis, and has spoken nationally and internationally on chronic liver disease. His many awards include the American Liver Foundation Award for Excellence, a Fullbright Scholarship, and the Mitchell Lectureship of the Royal College of Physicians. He is a member of the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.

Speaker Disclosure:
Nezam Afdhal, MD, has disclosed that he has received grants for clinical research from Schering Plough/Merck, Novartis, Glaxo Smith Kline, Echosens, Vertex, Gilead, Quest, Pharmasett, and Abbott. He has served as a consultant for and has participated in advisory boards for Gilead, Echosens, Glaxo Smith Kline, Vertex, Novartis, Boehringer Ingelheim, Ligand, Springbank, Medgenics, and Schering/Merck-Managed by HMS and BIDMC. He is a stockholder for Springbank and Medgenics.
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.